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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not a once 
daily topical application of fixed-dose combination gel containing adapalene 0.1%-benzoyl 
peroxide (BPO) 2.5% (adapalene-BPO) is effective at treating mild to moderate acne. 
 
STUDY DESIGN: Three multi-center double blind randomized control studies published in the 
English language between 2007-2013.  
 
STUDY SOURCES: Three peer-reviewed RCTS were found using Pubmed. These studies 
compared the same fixed-dose combination gel adapalene-BPO against placebo vehicles. Two 
studies also compared to additional groups receiving monotherapies.    
 
OUTCOMES MEASURED: Outcomes measured were improvement of participant’s acne 
according to the Investigator’s Global Assessment of Acne Severity (IGS), percentage change in 
acne lesions from baseline to post treatment, safety and tolerability assessment scales, 
participants’ assessment of their acne improvement, and Children’s Dermatology Life Quality 
Index. 
 
RESULTS:  The fixed-dose combination gel of adapalene-BPO demonstrated significant 
differences with total lesion counts and treatment efficacy. It was significantly more effective 
than monotherapies or a placebo vehicle for the treatment of mild to moderate acne. Adverse 
events were similar to those experienced with the monotherapies and mainly consisted of dryness 
and erythema that primarily occurred early in the studies.  
 
CONCLUSIONS: A once daily topical application of adapalene-BPO is effective at treating mild 
to moderate acne. Adapalene-BPO demonstrated superior efficacy, increased lesion count 
reduction, and a faster onset of action compared to monotherapies consisting of adapalene or 
benzoyl peroxide as well as a placebo vehicle.  
 
KEY WORDS: adapalene, benzoyl peroxide (BPO), adapalene-BPO, acne  
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INTRODUCTION 
Acne vulgaris is an inflammatory skin condition that is characterized by comedones, 
papules, pustules, nodules, and cysts.1 Acne is the most common skin disorder in the US 
affecting 40-50 million Americans. It is also the most commonly treated skin disease in the U.S. 
and has been estimated to affect approximately 85% of the population between ages 12 and 26 
years of age.1,3 Acne is one of the many multi-factorial variables highly associated with 
depression and other psychiatric processes. Balkrishnan et al (2006) found patients with acne 
demonstrated “a consistent relationship with anxiety, self-consciousness, inhibition of social 
interactions, and dissatisfaction with appearance”. 2 Acne has been shown to affect patient quality 
of life in a way that is comparable to the psychological effects of other chronic diseases. 2,4 With 
an estimated 5-6 million visits, acne continues to be an economic burden on many families with 
the total episode cost across age groups averaging $689.06 per episode. 2,4  In 2004 the direct cost 
associated with treatment of acne in the U.S. alone was $2.2 billion2,4  
The course can be self-limiting but the sequelae can be life long with risks of 
hypertrophic scarring. In twin studies 81% of the acne population variance was found due to 
genetic factors (vs. 19% environmental factors). 1 The pathogenesis includes multiple processes 
such as follicular epidermal hyperproliferation, excess sebum production, inflammation, and the 
presence of Propionibacterium acnes (P acnes) species on the skin. 9 P acnes antagonizes the 
toll-like receptor 2 in the skin to induce the production of inflammatory cytokines.5  
The intensity of medical treatment is based off of the amount of cystic lesions, open and 
closed comedones, and inflammatory lesions. For mild to moderate acne, topical treatments such 
antibacterials (clindamycin), salicylic acid, benzoyl peroxide, and retinoids (adapalene, retin-a) 
are typically employed. 1 For moderate to severe acne, oral antibiotics (tetracycline, doxycycline, 
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erythromycin, Bactrim) combined with topicals are prescribed. 1 Isotretinions (Accutane) are 
effective for severe cases or acne that is refractory to other treatment. 1  
Benzoyl peroxide is a safe and effective broad-spectrum bactericidal with no potential for 
inducing bacterial resistence.5,4 Due its potency, BPO is more effective than topical antibiotics 
against P. Acnes. 5,4 Its mechanism of action releases free-radical oxygen molecules that oxidize 
bacterial proteins located in the sebaceous follicles. This process eliminates P. Acnes and 
decreases fatty acids that irritate the sebaceous follicles. 5,4 
Topical retinoids such as adapalene decrease inflammation by targeting the body’s 
immune system response to inflammation.6,7 Their mechanism of action involves down 
regulating the surface toll-like receptors, cell differentiation, inflammatory mediators, migration 
of inflammatory cells, and cellular keratinization. 7 
Objective  
The objective of this selective EBM review is to determine whether or not a once daily 
topical application of fixed-dose combination gel containing adapalene 0.1%-benzoyl peroxide 
(BPO) 2.5% (adapalene-BPO) is effective at treating mild to moderate acne.  
Methods 
Criteria used for selection included; males and females with mild to moderate acne and an 
inflammatory lesion count ranging from 20-100. The intervention used in all three studies was a 
once daily topical application of adapalene 0.1%-benzoyl peroxide (BPO) 2.5% (adapalene-
BPO). The adapalene-BPO gel was applied to the intent to treat groups in all three studies once 
daily in the evening for 12 weeks. The control groups received a visually matched placebo gel. 
Comparisons in the pediatric population study consisted of a visually matched placebo vehicle in 
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the control group.8 Two studies utilized comparison groups that received monotherapies of either 
adapalene 0.1% or benzoyl peroxide 2.5% in addition to the controlled placebo group. 5,7 
Outcomes measured included success rate of the treatment based on the improvement of 
participants’ acne, the percentage change in lesions from the baseline to the end of the study, 
safety, tolerability, and the subjects’ personal assessments of their acne improvement. Pubmed 
was the primary data source utilized for this meta-analysis and all of the articles selected were 
published in peer-reviewed journals. The articles were selected based on their relevance to the 
objective and content consisting of patient-oriented evidence that matters (POEMS). All three 
articles were published in English and consisted of multi-center randomized double-blind 
controlled studies. Keywords used in the searches included “acne vulgaris”, “adapalene”, and 
“benzoyl peroxide”.  
Inclusion criteria included males and females ages 9 and older, mild to moderate acne, and 
20-100 inflammatory lesions (Table 1).  An IGA score of 3 or less was required for participants 
to qualify for the study and this same IGA scale was utilized to evaluate the efficacy of 
treatment.8 Specific washout periods were enforced in all three studies for participating subjects 
previously taking topical or systemic acne treatment medications.5,7,8 Exclusion criteria included 
individuals with severe nodular cystic acne, pregnant women, men with facial hair, and patients 
requiring oral therapy treatment (Table 1). Summary statistics were reported using p-values, 
NNT, NNH, RBI, ABI (Table 2).   
Outcomes measured in all three studies assessed POEMS. The Investigator’s Global 
Assessment (IGA) of acne severity was used to evaluate treatment efficacy and success in all 
three studies. IGA specifically defines the qualifications for a patient to receive a score of 0 – 4 
(0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe).5,7,8 The change in IGA was 
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assessed on a weekly basis throughout all three studies as well as the percentage change in lesion 
count from baseline, cutaneous tolerability, and adverse events. Compliance with intervention 
was not reported.  
Summary statistics were reported in all three studies using p-values. Success rate and 
percentage lesion count reduction were systematically analyzed in all three studies using the 
Cochran-Mantel Haenzel (CMH) test. The CMH test was then “stratified by analysis center using 
general association for success rates and row mean differences by relative to identified 
distribution transformed scores for percentage lesion changes.” 5,7,8 These analyses were repeated 
for the per-protocol groups. CMH was also used to analyze the subject’s assessment of their acne 
improvement. In all three studies, the outcomes tests were two-sided and used a .05 level to 
declare significance. Safety and tolerability were assessed weekly by investigators using a scale 
to rate erythema, dryness, stinging, burning with scores ranging from 0 (none) to 3 (severe). 5,7,8 
Eichenfield et al (2013) also investigated quality of life utilizing the Children’s Dermatology 
Life Quality Index (C-DLQI) at baseline and week 12.8  
1.) Table 1:  Demographics and Characteristics of included studies  
Study Type # pts Age 
(yr) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Eichenfield 
(2013) 8 
Double 
blind 
RCT 
283  9 – 11  - Males and 
females with 
mild to 
moderate acne 
vulgaris (score 
of 3 or less on 
IGA scale)  
-20-100 lesions 
on face 
-nodule or 
cystic acne 
lesions 
- severe acne 
that requires 
systemic 
treatment 
- use of 
hormonal 
contraceptives  
42 Fixed dose 
combination 
gel of 
adapalene 0.1% 
and benzoyl 
peroxide (BPO) 
2.5% 
(adapalene-
BPO) once 
daily in the 
evening for up 
to 12 weeks   
Gollnick 
(2009) 5 
Double 
blind 
RCT 
1670 12 + - males and 
females with 
mild to 
moderate acne 
- severe acne 
requiring 
isotretinoin 
therapy 
146 Fixed dose 
combination 
gel of 
adapalene 0.1% 
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- 20-50 
inflammatory 
lesions 
- IGA score of 
3  
- no more than 
1 active nodule  
- pregnant 
women 
- men with 
facial hair that 
would interfere 
with visiual 
assessments 
and benzoyl 
peroxide (BPO) 
2.5% 
(adapalene-
BPO) once 
daily in the 
evening for up 
to 12 weeks   
Thiboutot 
(2007) 7 
Double 
blind 
RCT 
517 12+ - Males and 
females with 
acne 
- 30-100 
noninflammato
ry facial 
lesions, 20-50 
inflammatory 
facial lesions  
- no nodules or 
cysts  
- Severe acne 
requiring 
isotretinoin 
therapy 
- women who 
were pregnant, 
nursing, or 
planning 
pregnancy 
- men with 
facial hair that 
would interfere 
with visual 
assessments 
47 Fixed dose 
combination 
gel of 
adapalene 0.1% 
and benzoyl 
peroxide (BPO) 
2.5% 
(adapalene-
BPO) once 
daily in the 
evening for up 
to 12 weeks   
 
RESULTS 
The studies in this meta-analysis were multi-center randomized double-blind controlled 
studies conducted in a clinical setting. All three studies required participants with an IGA scale 
of 3 (moderate acne) with slight variations in the inclusions criteria. Thiboutot et al (2007) 
confirmed their inclusion sample by having blinded third party dermatologists review photos 
taken of participants at the selection screening.7 Eichenfield et al (2013) modified the IGA scale 
to apply to the pediatric population. 8 Gollnick et al (2009) and Thiboutot et al (2007) included 
males and females ages 12 and older, while Eichenfield et al (2013) included only male and 
female children ages 9 to 11 years old. 5,7,8 Gollnick et al (2009) and Thiboutot et al (2007) also 
included additional experimental groups that solely received either adapalene or benzoyl 
peroxide as a monotherapy treatment in addition to a controlled placebo vehicle group. 7,8 
Exclusion criteria in all three studies included the presence of cystic acne lesions or severe acne 
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requiring isotretinoin or systemic therapy. Gollnick et al (2009) and Thiboutot et al (2007) 
excluded pregnant or nursing women and men with facial hair that interfered with assessment of 
their skin. 7,8 All three studies defined efficacy and success of treatment based on the percentages 
of patients with ‘clear’ or ‘almost clear’ ratings on the IGA score.  
For success rate and efficacy of treatment, Gollnick et al (2009) found the adapalene-
BPO combination (37.9%) superior to all other treatment and placebo groups (17.9%, p <.05) 
(Table 2).  The numbers needed to treat are 3 (Table 2). The adapalene-BPO also demonstrated 
the greatest reductions in inflammatory lesions counts relative to the other treatments by as early 
as week 1 in the study (p < .05) and continued to remain superior by week 12 (p < .05).  
Eichenfield et al (2013) also utilized the IGA scale and total lesion count to assess the 
efficacy the adapalene-BPO in the ITT group.8 Since they focused on a specific population of 
children they also utilized the C DLQI at baseline and week 12. At week 12, 71.0% of the intent 
to treat (ITT) group reported their acne had no effect on their quality of life vs. 57.5% in the 
control group. At week 12, the efficacy and success of adapalene-BPO was significantly superior 
to the vehicle.8 Approximately half of the subjects (49.3%) were rated ‘clear’ or ‘almost clear’ 
compared to 15.9% of the placebo group (p < .05).  The numbers needed to treat were 3 (Table 
2). According to Eichenfield et al (2013), while the adapalene-BPO ITT group presented with 
decreased lesion counts as early as week 1 (p < .05), the vehicle percentage change in total and 
non-inflammatory lesions “plateaued and worsened for inflammatory lesions between weeks 8 
and 12.” 8 
Thiboutot et al (2007) had similar findings with the success rate and efficacy of the 
adapalene-BPO combination (27.5%) compared to the placebo group (9.9%, p < .05) (Table 2).7 
The numbers needed to treat were 6 (Table 2). The lesion counts on participants including total, 
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inflammatory, and non-inflammatory after 12 weeks of treatment also revealed a significantly 
greater response to the combination therapy relative to placebo and monotherapy groups (p 
values < 0.05).   
Overall, statistically significant findings using the combination gel were observed across 
all studies. 5,7,8 Not only did the studies demonstrate adapalene-BPO to be effective at treating 
acne compared to groups receiving a placebo vehicle, but Gollnick et al (2009) also found the 
adapalene-BPO (37.9%) superior and statistically significant to the groups that received the 
monotherapy of only adapalene (21.8%, p <.05)  or BPO (26.7%, p <.05). 5 Thiboutot et al 
(2007) reported similar statistically significant findings when comparing the adapalene-BPO 
treatment group (27.5%) to the monotherapy groups receiving either adapalene (15.5%, p <.05) 
or benzoyl peroxide (15.4%, p <.05).7  
SAFETY  
 All three studies assessed safety based on tolerability and adverse events such as 
erythema, dryness, scaling, and burning. In the study performed by Gollnick et al (2009), the 
overall incidence of participants experiencing at least one adverse event was 48% for the 
adapalene-BPO and 28% for the vehicle (Table 3). The numbers needed to harm were 5 (Table 
3). No serious adverse events were deemed related to the study treatments and the adverse events 
that appeared to be related were primarily dermatological in nature consisting of erythema and 
dry skin. 5 According to Gollnick et al (2009) these adverse events “occurred early in the study, 
and resolved without residual effects.” 5  
According to Thiboutot et al (2007) the overall incidence of subjects experiencing at least 
one adverse event was 38%  for the adapalene-BPO group and 26.8% for the vehicle (Table 3).7 
The numbers needed to harm were 9 (Table 3). No serious adverse events were deemed related 
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to the study treatments. Some of the incidents that were deemed “un-related” to the study 
included illicit drug overdose and social circumstances. The most frequently reported adverse 
event was dry skin.7 
According to Eichenfield et al (2013) mean scores for adverse side effects did not exceed 
a score of 1 (mild) for both the ITT population and vehicle group.8 There were 29 subjects (20%) 
who experienced treatment-related AE and 1 subject (0.7%) in the vehicle group. The numbers 
needed to harm were 8 (Table 3). The incidence of adverse side effects peaked for the adapalene-
BPO in the first two weeks of treatment. However, Eichenfield et al (2013) reported these 
adverse side effects such as redness and irritation “remained mild and then disappeared over time 
to reach a tolerability level comparable to vehicle as week 4”. 8 The most common adverse effect 
was skin burning sensation (9.2%) and skin irritation (5.6%). 8 
Table 2. Efficacy of adapalene-BPO in the treatment of acne (dichotomous data)  - NNT 
Study Control 
Event Rate 
(CER) 
Experimental 
Event Rate 
(EER) 
P value  Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Numbers 
needed to 
treat (NNT) 
Gollnick et 
al (2009) 5 
17.9% 37.9% P < 0.05* 1.12 0.2 5 
Eichenfield 
et al (2013) 8 
15.9% 49.3% P < 0.05* 2.10 0.334 3 
Thiboutot et 
al (2007)7 
9.9% 27.5% P < 0.05* 1.8 0.176 6  
*statistically significant differences  
Table 3.  Adverse effects of adapalene-BPO in the treatment of acne (dichotomous data ) – NNH  
Study EER CER RRI ARI Numbers 
needed to harm 
(NNH) 
Gollnick et al 
(2009) 5 
48% 28% 0.71 0.2 5 
Eichenfield et 
al (2013) 8 
20% 7% 1.9 0.13 8 
Thiboutot et al 
(2007) 7 
38.3% 26.8% 0.4 0.12 9  
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Discussion  
Adapalene-BPO is marketed and sold under the brand name Epiduo.6 There is currently no 
generic available, limiting the availability to consumers until the patent expires. The average cost 
of a 45 g tube of Epiduo gel is $376.20.6 Although some insurances may cover the prescription, 
the Epiduo drug manufacturer offers coupons enabling consumers to pay $25 for their first 
prescription, $15 for the first refill, and $10 for following refills.9 However, without adequate 
insurance or access to these coupons, the expense of the product limits its availability. An 
alternative for consumers is to buy adapalene (0.1%) topical gel and benzoyl peroxide (BPO) 
separately.6  
Current research trials have not demonstrated any long-term effects aside from increased 
photosensitivity while on the medication. 6 The FDA has not issued any black box warnings 
although Epiduo remains in pregnancy category C and excretion in breast milk is unknown. 6 
Other adverse effects such as dryness, scaling, erythema, burning/stinging, are commonly 
experienced in the first four weeks of treatment and usually decrease with continued use. 6  
All three studies were controlled research trials that cannot precisely reflect the efficacy and 
safety in the general population.8 Eichenfield  et al (2013) performed one of the few clinical 
studies focusing on the treatment of pediatric acne. However, a major limitation affecting the 
reliability of their study is a lack of diversity in their participants: 76.1% of their subjects were 
females and 81% of their subjects were Caucasian.8 Another limitation found in all three studies 
is the limited time frame of 12 weeks. Although this is a common length of time to evaluate 
efficacy and safety of dermatological FDA-approved medications, it is possible for adverse side 
effects to manifest after this three month period.  
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Overall, all three studies found adapalene-BPO to be superior and statistically significant 
compared to the placebo groups at treating acne. 5,7,8 Adapalene-BPO was found to have a 
significantly greater and faster onset of action at improving acne as well as the greatest 
reductions in inflammatory lesions compared to the placebo group or those receiving 
monotherapies. 5,7,8 The numbers needed to treat in all three studies were low, supporting the 
efficacy of the treatment in terms of patient oriented medicine (Table 2). The numbers needed to 
harm were higher than the numbers needed to treat, but they still remained within a close range 
to those needed to treat (Table 3). Higher numbers need to harm would be preferable to support 
the efficacy and success of adapalene-BPO, but it is important to note that the incidence of 
reported adverse effects in patients receiving the monotherapies solely BPO or adapalene 
remained comparable or higher to those receiving the combination therapy.7,8 
 
CONCLUSION 
This meta-analysis has demonstrated that a once daily topical application of a combination 
gel containing adaplene 0.1%-benzoyl peroxide (BPO) 2.5% is effective at improving acne. 
Gollnick et al (2009) and Thiboutot et al (2007) found adapalene-BPO to be significantly more 
effective and to have a faster onset of action than adapalene or BPO used as monotherapies.5,7  
Retinoids such as adapalene have been found to permanently alter the toll-like receptors 
on the skin.7 Future study is warranted to evaluate if patients continue to experience long-term 
clearer skin effects after completing a treatment with adapalene-BPO. These studies could help 
determine an adequate treatment time required to permanently change the toll-receptors and 
enable patients to maintain clearer skin indefinitely. These future studies can also investigate 
adverse effects experienced by patients using adapalene-bpo longer than 12 weeks.  
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With the concerning and increasing incidence of antibiotic resistance, adapalene-BPO 
may become a vital treatment resource in the future of medicine. Future studies could investigate 
if adapalene-BPO has a decreased incidence of bacterial resistance compared to oral and topical 
antibiotics used to treat acne. Patient adherence to treatment with once daily Adapalene-BPO 
could also be compared to those patients treated with multiple daily dosing of antibiotics. It is 
possible the once daily dosing of adapalene-BPO could shorten the time for visible signs of acne 
improvement if patients are more likely to adhere to the treatment routine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
1.)  Zaenglein AL, Graber EM, Thiboutot DM. Chapter 80. Acne Vulgaris and Acneiform 
Eruptions. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff 
K. eds. Fitzpatrick's Dermatology in General Medicine, 8e. New York, NY: McGraw-
Hill; 
2012. http://accessmedicine.mhmedical.com/content.aspx?bookid=392&Sectionid=41138
785. Accessed October 05, 2014.  
2.) Balkrishnan R, Kulkarni AS, Cayce K, Feldman SR. Predictors of healthcare outcomes 
and costs related to medication use in patients with acne in the united states. Therapeutics 
for the Clinician. Cutis. 2006;77:251-255.  
3.) Inglese MJ, Fleischer AB, Feldman SR, Balkrishnan R. The pharmacoeconomics of acne 
treatment: where are we heading? J Dermatological Treatment. 2008 Oct; 19: 27-37 
4.) Yentzer BA, Hick J, Reese EL, Uhas A, Feldman SR, Balkrishnan R. Acne vulgaris in 
the United States: a descriptive epidemiology. Cutis. 2010;86(2):94-9. 
5.) Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu 
Y, Graeber M; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique 
fixed-dose combination topical gen for the treatment of acne vulgaris; a transatlantic, 
randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009 
Nov;161(5):1180-9. 
6.)  Lexi-Comp ONLINE [database online]. Adapalene and benzoyl peroxide (Lexi-Drugs). 
Hudson, OH: Lexi-Comp Inc; 2014. http://online.lexi.com. Accessed November 21, 
2014.  
7.) Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, 
Kang S; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose 
combination for the treatment of acne vulgaris: results of a multicenter, randomized 
double-blind, controlled study. J Am Acad Dermatol. 2007 Nov;57(5):791-9. 
8.) Eichenfield LF, Draelos Z, Lucky AW, Hebert AA, Sugarman J, Stein Gold L, Rudisill 
D, Liu H, Manna V. Preadolescent moderate acne vulgaris: a randomized trial of the 
efficacy and safety of topical adapalene-benzoyl peroxides. J Drugs Dermatol. 2013 Jun 
1; 12(6):611-8. 
9.) Save on Epiduo Gel. Galderma Epiduo Website. Published 2014. 
www.epiduo.com/rebate_register.aspx. Accessced November 20, 2013. 
 
